Ming Bioventures
VC Fund
Suzhou, China
Ming Bioventures is a professional venture capital institution focusing on innovative medicines, medical devices & new diagnostics.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries Ming Bioventures invests in
Stages Ming Bioventures invests in
Countries Ming Bioventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Hua Guo
|
|||
Investment Focus
Industry
- Health Care 14 (52%)
- Biotechnology 13 (48%)
- Medical 9 (33%)
- Biopharma 6 (22%)
- Medical Device 6 (22%)
Stage
- Series B 8 (30%)
- Seed 5 (19%)
- Series A 4 (15%)
- Series C 4 (15%)
- Funding Round 3 (11%)
Country
- China 18 (67%)
- United States 4 (15%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hua Guo
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Mingcheng Biotechnology
|
Mingcheng Biotechnology is a biotechnology company focused on research and experimental development. | Seed / Mar 20, 2026 | |
Artheia
|
Artheia is a cutting-edge medical device firm that specializes in ophthalmology and offers a diverse product line. Artheia is working on a line of smart optometry products for myopia prevention and control, vision protection, low vision aids, and dry eye disease treatment, as well as for optometry clinics and communities. | $1.4M / Seed / Jan 28, 2024 | |
Innovo Therapeutics
|
Innovo Therapeutics is a anti-cancer drug developer committed to research and creation of medications that target protein breakdown. | $14.1M / Seed / Dec 01, 2023 | |
Beyond Therapeutics
|
Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs. | Seed / Jul 17, 2023 | |
Tyligand Bioscience
|
Tyligand Bioscience is a biotechnology company that focuses on the discovery and development of small molecule therapeutics to help patients with cancer and autoimmune diseases. Tyligand's pharmaceuticals are designed to target and treat tumors and autoimmune disorders, enabling healthcare professionals to prescribe more effective medicine andimprove health outcomes. | Series A / Jul 08, 2023 | |
Su Hui therapy
|
HealiRNA develops infectious disease vaccines, tumor vaccines, cell therapy, and protein replacement. They provide mRNA drug research and development, production, clinical trial design, and data analysis services. | $14.5M / Seed / Mar 10, 2023 | |
Shengyuan MicroPort
|
Shengyuan MicroPort is a developer of an intelligent and precise minimally invasive diagnosis and treatment platform. | $13M / Series B / Dec 30, 2022 | |
Mesai Biotech
|
Mesai Biotech is a macromolecule drug developer, focusing on the development of new macrophage targets in the tumor immune microenvironment. | Series A / Sep 02, 2022 | |
Redbud Medicine
|
Redbud Medicine focuses on real-time data analysis during innovation and trials, provides innovative and efficient clinical development services for biotechnology companies in China and around the world, helps local Chinese biotechnology companies bring their products to the global market, and helps foreign biotechnology companies. Technologycompanies bring their products to China. | $10M / Series A / Aug 23, 2022 | |
|
Innovo Therapeutics
|
Innovo Therapeutics is a anti-cancer drug developer committed to research and creation of medications that target protein breakdown. | $14.7M / Angel / May 13, 2022 | |
| See all 27 investments → | |||
Co-Investors
Addor Capital
2 deals together
BioVenture
2 deals together
Cowin Capital
2 deals together
HSG
2 deals together
JMCR Partners
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ming Bioventures invest in?
Ming Bioventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Seed stage. Most of the 27 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ming Bioventures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Ming Bioventures?
The team at Ming Bioventures includes Hua Guo (Founder & Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
